Sanofi | Pharma Commons 2012-07-10 07:29:53

Snubbed by regulators and experts alike, Sanofi ($SNY) is reeling back all its global marketing applications for semuloparin (Mulsevo). The drug is designed to prevent blood clots from forming in chem…
Read the full story: News